No Picture
Trading Ideas

Robinhood Crypto expands to 8 more US states, bringing the total to 47 states

Investment app provider Robinhood has brought its commission-free cryptocurrency trading service to 8 more U.S. states. The added states are Delaware, Kentucky, Louisiana, Maine, Maryland, Minnesota, Nebraska, and Vermont, according to an announcement Thursday.The post Robinhood Crypto expands to 8 more US states, bringing the total to 47 states appeared first on The Block. …read more […]

No Picture
Trading Ideas

RPT-Peugeot's turnaround driver, Tavares, faces his biggest challenge

Carlos Tavares, a former Renault star credited with reviving the company’s French rival Peugeot SA, has long shone as a restructurer-in-chief, staring down unions and slicing down bureaucracies. Combining Peugeot and Fiat Chrysler Automobiles NV would create the fourth-largest global auto manufacturer, a big advantage for amortizing investments in electric vehicles and getting the best prices from parts suppliers. The auto industry faces “ten years of chaos,” Tavares told reporters at September’s Frankfurt auto show. …read more […]

No Picture
Trading Ideas

World’s Largest Pension Fund Sees Gain as Japan Stocks Rally

(Bloomberg) — The world’s biggest pension fund posted a gain for a third consecutive quarter, with Japanese stocks providing the best return among assets amid a global shift to value shares in September.Japan’s Government Pension Investment Fund returned 1.1%, or 1.8 trillion yen ($17 billion), in the quarter ended Sept. 30, with assets totaling 161.8 trillion yen, it said Friday in Tokyo. Domestic stocks were the fund’s best performing investment, gaining 3.3%, while foreign equities added 0.1%. The return was 1.2% for overseas bonds and 0.3% for Japanese debt.The GPIF’s results were the first since the fund announced last month …read more […]

No Picture
Trading Ideas

Novartis arthritis drug fails to prove it is significantly better than rival

A clinical trial of Novartis’s Cosentyx drug has failed to prove it is significantly better than a rival treatment for a type of arthritis, the Swiss company said on Friday. Novartis said Cosentyx, when used to treat active psoriatic arthritis, “narrowly missed statistical significance for superiority” versus Humira, a drug made by AbbVie. “While Cosentyx narrowly missed statistical significance for superiority…. it showed numerically higher results versus Humira,” Novartis said following the results of a head-to-head trial. …read more […]